Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Rex

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenograftsH Toni Jun, Jan Sun, Karen Rex, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 26, 2024
Xenografted Tumors Share Comparable Fraction Unbound and Can Be Surrogated by Mouse Lung TissueMin Wang, Sandip Kuldharan, Aravind Shenoy, et al.
Molecular Cancer Therapeutics|May 14, 2009
Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal modelsAngela Coxon, Karen Rex, Susanne Meyer, et al.
Nuclear Medicine and Biology|March 5, 2013
Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft modelKaren Rex, Xiaoman Z Lewis, Sundaresan Gobalakrishnan, et al.
Journal of Medicinal Chemistry|February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivativesMark H Norman, Longbin Liu, Matthew Lee, et al.
Arthritis and Rheumatism|October 18, 2002
Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritisAngela Coxon, Brad Bolon, Juan Estrada, et al.
Cancers|January 21, 2023
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor SignalingFabiola Cecchi, Karen Rex, Joanna Schmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptorsAngela Coxon, Tammy Bush, Douglas Saffran, et al.
Molecular Cancer Therapeutics|October 15, 2009
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcomaChong-Feng Gao, Qian Xie, Yu-Wen Zhang, et al.
Molecular Cancer Therapeutics|May 20, 2016
Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular CarcinomaZhiqiang Du, Sean Caenepeel, Yuqing Shen, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenograftsH Toni Jun, Jan Sun, Karen Rex, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 26, 2024
Xenografted Tumors Share Comparable Fraction Unbound and Can Be Surrogated by Mouse Lung TissueMin Wang, Sandip Kuldharan, Aravind Shenoy, et al.
Molecular Cancer Therapeutics|May 14, 2009
Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal modelsAngela Coxon, Karen Rex, Susanne Meyer, et al.
Nuclear Medicine and Biology|March 5, 2013
Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft modelKaren Rex, Xiaoman Z Lewis, Sundaresan Gobalakrishnan, et al.
Journal of Medicinal Chemistry|February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivativesMark H Norman, Longbin Liu, Matthew Lee, et al.
Arthritis and Rheumatism|October 18, 2002
Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritisAngela Coxon, Brad Bolon, Juan Estrada, et al.
Cancers|January 21, 2023
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor SignalingFabiola Cecchi, Karen Rex, Joanna Schmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptorsAngela Coxon, Tammy Bush, Douglas Saffran, et al.
Molecular Cancer Therapeutics|October 15, 2009
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcomaChong-Feng Gao, Qian Xie, Yu-Wen Zhang, et al.
Molecular Cancer Therapeutics|May 20, 2016
Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular CarcinomaZhiqiang Du, Sean Caenepeel, Yuqing Shen, et al.
Pageof 4